The pharmacokinetic profile of voriconazole during continuous high-volume venovenous hemofiltration in a critically ill patient

被引:16
作者
Quintard, Herve [1 ,2 ]
Papy, Enunanuelle
Massias, Laurent
Lasocki, Sigismond [2 ]
Arnaud, Philippe
Desmonts, Jean-Marie [2 ]
Montravers, Philippe [2 ]
机构
[1] St Roche Hosp, Intens Care Unit, F-06000 Nice, France
[2] Hop Bichat Claude Bernard, Div Intens Care, Paris, France
关键词
antifungals; renal failure; hemofiltration; pharmacokinetics;
D O I
10.1097/FTD.0b013e31815c1672
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
In critically ill patients, dosage adjustment of voriconazole could be helpful when high-volume continuous venovenous hemofiltration is needed. Voriconazole pharmacokinetics were studied in an anuric critically ill patient, under high-volume continuous venovenous hemofiltration, over an interval period after a 4-mg/kg dose of voriconazole. Arterial and effluent voriconazole concentrations were measured after liquid phase extraction using a high-pressure liquid chromatography. The extrapolate area under the curve(0-12h) of voriconazole was 65 mg/h/L. The total body clearance of voriconazole was 5.4 L/h with a half-life of 16.5 hours and a distribution volume of 12.6 L. The estimated sieving coefficient was 0.58 and the filtration clearance 1.39 L/h. High-volume. continuous venovenous hemofiltration could affect voriconazole disposition in contrast with other techniques. Besides, we observed voriconazole accumulation consequence of the saturation of the metabolic clearance resulting from multiple organ failure. Dosage adjustment seems to be required in these conditions, but this observation must be confirmed by a clinical study.
引用
收藏
页码:117 / 119
页数:3
相关论文
共 17 条
[1]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571
[2]   A rapid HPLC assay for voriconazole in human plasma [J].
Gage, R ;
Stopher, DA .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (08) :1449-1453
[3]   Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype [J].
Geist, Marcus J. P. ;
Egerer, Gerlinde ;
Burhenne, Juergen ;
Mikus, Gerd .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) :3227-3228
[4]   HIGH-VOLUME HEMOFILTRATION IMPROVES RIGHT VENTRICULAR-FUNCTION IN ENDOTOXIN-INDUCED SHOCK IN THE PIG [J].
GROOTENDORST, AF ;
VANBOMMEL, EFH ;
VANDERHOVEN, B ;
VANLEENGOED, LAMG ;
VANOSTA, ALM .
INTENSIVE CARE MEDICINE, 1992, 18 (04) :235-240
[5]   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].
Herbrecht, R ;
Denning, DW ;
Patterson, TF ;
Bennett, JE ;
Greene, RE ;
Oestmann, JW ;
Kern, WV ;
Marr, KA ;
Ribaud, P ;
Lortholary, O ;
Sylvester, R ;
Rubin, RH ;
Wingard, JR ;
Stark, P ;
Durand, C ;
Caillot, D ;
Thiel, E ;
Chandrasekar, PH ;
Hodges, MR ;
Schlamm, HT ;
Troke, PF ;
de Pauw, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415
[6]  
Imhof A, 2006, SWISS MED WKLY, V136, P739
[7]   Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes [J].
Murayama, Norie ;
Imai, Naoko ;
Nakane, Takahisa ;
Shimizu, Makiko ;
Yamazaki, Hiroshi .
BIOCHEMICAL PHARMACOLOGY, 2007, 73 (12) :2020-2026
[8]   Candidemia in non-neutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy [J].
NollaSalas, J ;
SitgesSerra, A ;
LeonGil, C ;
MartinezGonzalez, JM ;
LeonRegidor, MA ;
IbanezLucia, P ;
TorresRodriguez, JM .
INTENSIVE CARE MEDICINE, 1997, 23 (01) :23-30
[9]   Voriconazole: A new triazole antifungal agent [J].
Pearson, MM ;
Rogers, D ;
Cleary, JD ;
Chapman, SW .
ANNALS OF PHARMACOTHERAPY, 2003, 37 (03) :420-432
[10]   Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety [J].
Purkins, L ;
Wood, N ;
Greenhalgh, K ;
Allen, MJ ;
Oliver, SD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 :10-16